Learn why Congress created the 340B program, which safety-net providers can participate, and how discounted outpatient drugs help clinics stretch limited resources and expand patient care.

Meet the major players in the 340B ecosystem and understand how products, payments, and reimbursements move among them. Learn why the covered entity remains at the center of the program and ultimately responsible for it.

Follow a prescription from discounted drug acquisition through payer reimbursement to understand how 340B generates net proceeds. See how those proceeds can become meaningful resources for patient care.

Explore how grantees can reinvest 340B proceeds into uncompensated care, expanded services, and community programs. Real-world examples demonstrate how clinics turn savings into greater access and better outcomes.

Understand the differences between funded FQHCs and FQHC Look-Alikes, including the pathways and requirements for each. Learn how organizational readiness and scope of project shape 340B eligibility.

Explore the direct-funding, subrecipient, and in-kind pathways to 340B eligibility through Section 318. Learn why health department relationships and clear documentation are essential to establishing eligibility.

Learn how the different parts of the Ryan White HIV/AIDS Program confer 340B eligibility and which patients they cover. Explore practical ways to identify and pursue Ryan White funding opportunities.

Understand the major pathways through which safety-net organizations qualify for 340B. Learn how grants, eligible sites, supporting documentation, and scope of project determine the extent of your eligibility.

Understand what effective 340B policies and procedures should cover and why they must reflect your actual operations. Learn how thoughtful customization, consistent execution, and regular review support audit readiness.

Learn what constitutes diversion and where risk commonly arises across providers, pharmacies, referrals, and care settings. Explore the documentation and operational controls needed to defend patient eligibility.

Learn which prescription drugs and biologic products may qualify for 340B pricing, as well as which products are generally excluded. Understand how to establish, document, and consistently apply a defensible definition.

Understand Medicaid carve-in and carve-out decisions and why duplicate-discount prevention is a core compliance requirement. Learn how to evaluate state rules, reimbursement, claims identification, and operational feasibility.

Learn how OPAIS registration windows, effective dates, and contract-pharmacy requirements affect your launch timeline. Understand what must be in place to avoid losing access to 340B pricing for an entire quarter.

Compare building and operating an in-house pharmacy independently with partnering with an experienced pharmacy vendor. Evaluate each approach based on cost, control, expertise, launch speed, sustainability, and mission alignment.

Learn how pharmacy location affects patient convenience, prescription capture, clinical coordination, and program operations. Compare on-site and off-site models and understand the registration requirements associated with each.

Explore how contract pharmacies can expand patient access without requiring your organization to build its own pharmacy. Weigh those benefits against compliance risk, Medicaid limitations, reduced clinical coordination, and manufacturer restrictions.

Build a comprehensive strategy spanning staffing, medication revenue, patient experience, technology, compliance, and financial performance. Learn how to monitor results and adapt as your pharmacy and the broader market evolve.

Learn how patient adoption, provider engagement, and capture rate drive both clinical impact and financial sustainability. Explore practical tactics for transitioning prescriptions and creating an experience patients value.

Explore the four decisions that shape a pharmacy launch: inventory model, physical space, financial requirements, and implementation timeline. Learn how licensing, construction, staffing, and payer enrollment affect launch readiness.

Understand why state AIDS Drug Assistance Programs are facing increasing financial pressure and how coverage changes can affect patients. Learn how clinics can monitor state policy, advocate for access, and prepare additional support.

Learn how Medicare drug-price negotiation and a potential rebate model could affect 340B savings, working capital, and pharmacy operations. Explore how to model exposure and prepare for new claims and reconciliation requirements.

Follow the expansion of manufacturer restrictions across contract and entity-owned pharmacies. Understand how claims-data requirements, state protections, and changing grantee exemptions may influence your pharmacy strategy.

Explore how uncertainty surrounding HIV and STD funding could affect both patient services and 340B eligibility. Learn how monitoring, advocacy, and redundant eligibility pathways can help protect your organization.

Understand what is driving increased scrutiny of the 340B program and which sectors are responsible for its growth. Learn why grantees may still be affected by reforms despite representing a small share of total purchases.